April 29, 2020 / 9:53 AM / a month ago

BRIEF-AstraZeneca Says 20-25% Of Oncology Sales Came From Infused Medicines

April 29 (Reuters) - AstraZeneca PLC:

* ASTRAZENECA EXEC SAYS MORE THAN HALF OF SALES IN CANCER THERAPY TAGRISSO IN Q1 CAME FROM OUTSIDE U.S. - MEDIA CALL

* ASTRAZENECA EXEC SAYS ECONOMY IN CHINA IS RESTARTING; SEES UPTICK IN PATIENT DEMAND AS NON-COVID-19 PATIENTS COME INTO HOSPITALS - MEDIA CALL

* ASTRAZENECA - RESPIRATORY PRODUCTS SYMBICORT & FASENRA SAW DEMAND AS GUIDELINES SAY ASHTMA/COPD PATIENTS SHOULD STAY ON THERAPY AMID VIRUS OUTBREAK

* ASTRAZENECA EXEC SEES UNWINDING OF EXCESSIVE STOCK-KEEPING MOST LIKELY OVER THE NEXT 3-6 MONTHS - MEDIA CALL

* ASTRAZENECA EXEC SAYS 20-25% OF ONCOLOGY SALES IN Q1 CAME FROM INFUSED MEDICINES, BALANCE FROM ORAL; ADDS ORAL DRUGS HAD FEWER OBSTACLES IN TREATMENT Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below